Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance
will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for
12 months with the aim of reducing polyp burden.